{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T19:29:54Z","timestamp":1784748594507,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,12]],"date-time":"2010-02-12T00:00:00Z","timestamp":1265932800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1245\/s10434-010-0963-x","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T17:17:33Z","timestamp":1265908653000},"page":"1657-1661","source":"Crossref","is-referenced-by-count":30,"title":["Utility of FDG PET\/CT and Brain MRI in Melanoma Patients with Increased Serum S-100B Level During Follow-up"],"prefix":"10.1245","volume":"17","author":[{"given":"Tjeerd S.","family":"Aukema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato A. Vald\u00e9s","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina M.","family":"Korse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin B. R.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel W. J. M.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M. G.","family":"Bonfrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omgo E.","family":"Nieweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,12]]},"reference":[{"key":"963_CR1","first-page":"1898","volume":"31A","author":"HB Guo","year":"1995","unstructured":"Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:1898\u2013902.","journal-title":"Eur J Cancer"},{"key":"963_CR2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0959-8049(02)00487-2","volume":"39","author":"T Banfalvi","year":"2003","unstructured":"Banfalvi T, Gilde K, Gergye M, Boldizsar M, Kremmer T, Otto S. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma. Eur J Cancer. 2003;39:164\u20139.","journal-title":"Eur J Cancer"},{"key":"963_CR3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2004.10.019","volume":"41","author":"LH Smit","year":"2005","unstructured":"Smit LH, Korse CM, Hart AA, Bonfrer JM, Haanen JB, Kerst JM, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer. 2005;41:386\u201392.","journal-title":"Eur J Cancer"},{"key":"963_CR4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.2008.17.1777","volume":"27","author":"AA Tarhini","year":"2009","unstructured":"Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27:38\u201344.","journal-title":"J Clin Oncol"},{"key":"963_CR5","first-page":"2297","volume":"28","author":"LH Smit","year":"2008","unstructured":"Smit LH, Nieweg OE, Mooi WJ, Bonfrer JM, Haanen JB, Kroon BB, et al. Value of serum S-100B for prediction of distant relapse and survival in stage III B\/C melanoma. Anticancer Res. 2008;28:2297\u2013302.","journal-title":"Anticancer Res"},{"key":"963_CR6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00000658-199805000-00017","volume":"227","author":"WD Holder Jr","year":"1998","unstructured":"Holder WD, Jr, White RL, Jr, Zuger JH, Easton EJ, Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764\u20139.","journal-title":"Ann Surg"},{"key":"963_CR7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.03.5634","volume":"24","author":"MJ Reinhardt","year":"2006","unstructured":"Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET\/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol. 2006;24:1178\u201387.","journal-title":"J Clin Oncol"},{"key":"963_CR8","first-page":"1323","volume":"45","author":"D Fuster","year":"2004","unstructured":"Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med. 2004;45:1323\u20137.","journal-title":"J Nucl Med"},{"key":"963_CR9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/147323000703500415","volume":"35","author":"C Akcali","year":"2007","unstructured":"Akcali C, Zincirkeser S, Erbagcy Z, Akcali A, Halac M, Durak G, et al. Detection of metastases in patients with cutaneous melanoma using FDG-PET\/CT. J Int Med Res. 2007;35:547\u201353.","journal-title":"J Int Med Res"},{"key":"963_CR10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12149-008-0145-0","volume":"22","author":"K Kitajima","year":"2008","unstructured":"Kitajima K, Nakamoto Y, Okizuka H, Onishi Y, Senda M, Suganuma N, et al. Accuracy of whole-body FDG-PET\/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med. 2008;22:595\u2013602.","journal-title":"Ann Nucl Med"},{"key":"963_CR11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1148\/radiol.2261010920","volume":"226","author":"EM Rohren","year":"2003","unstructured":"Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226:181\u20137.","journal-title":"Radiology"},{"key":"963_CR12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/172460080502000106","volume":"20","author":"LH Smit","year":"2005","unstructured":"Smit LH, Korse CM, Bonfrer JM. Comparison of four different assays for determination of serum S-100B. Int J Biol Markers. 2005;20:34\u201342.","journal-title":"Int J Biol Markers"},{"key":"963_CR13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1365-2133.2000.03649.x","volume":"143","author":"L Brochez","year":"2000","unstructured":"Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol. 2000;143:256\u201368.","journal-title":"Br J Dermatol"},{"key":"963_CR14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000011989","volume":"56","author":"A Hauschild","year":"1999","unstructured":"Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999; 56:338\u201344.","journal-title":"Oncology"},{"key":"963_CR15","first-page":"1311","volume":"21","author":"G Krahn","year":"2001","unstructured":"Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001;21:1311\u20136.","journal-title":"Anticancer Res"},{"key":"963_CR16","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1245\/s10434-009-0629-8","volume":"16","author":"S Kruijff","year":"2009","unstructured":"Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009;16:3455\u201362.","journal-title":"Ann Surg Oncol"},{"key":"963_CR17","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2001.19.3.824","volume":"19","author":"ED Martenson","year":"2001","unstructured":"Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824\u201331.","journal-title":"J Clin Oncol"},{"key":"963_CR18","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1046\/j.1365-2133.1999.02905.x","volume":"140","author":"A Hauschild","year":"1999","unstructured":"Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and\/or immunotherapy. Br J Dermatol. 1999;140:1065\u201371.","journal-title":"Br J Dermatol"},{"key":"963_CR19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00008390-200302000-00008","volume":"13","author":"AP Hamberg","year":"2003","unstructured":"Hamberg AP, Korse CM, Bonfrer JM, De Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45\u20139.","journal-title":"Melanoma Res"},{"key":"963_CR20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00008390-200010000-00007","volume":"10","author":"B Schlagenhauff","year":"2000","unstructured":"Schlagenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Schwarz M, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res. 2000;10:451\u20139.","journal-title":"Melanoma Res"},{"key":"963_CR21","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1007\/s00259-007-0403-8","volume":"34","author":"K Strobel","year":"2007","unstructured":"Strobel K, Skalsky J, Kalff V, Baumann K, Seifert B, Joller-Jemelka H, et al. Tumour assessment in advanced melanoma: value of FDG-PET\/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging. 2007;34:1366\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"963_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000081482","volume":"210","author":"R Dummer","year":"2005","unstructured":"Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology. 2005;210:39\u201344.","journal-title":"Dermatology"},{"key":"963_CR23","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/MNM.0b013e3283043a0c","volume":"29","author":"IA Ho Shon","year":"2008","unstructured":"Ho Shon IA, Chung DK, Saw RP, Thompson JF. Guidelines for imaging in cutaneous melanoma. Nucl Med Commun. 2008;29:877\u20139.","journal-title":"Nucl Med Commun"},{"issue":"Suppl 1","key":"963_CR24","first-page":"72S","volume":"45","author":"H Schoder","year":"2004","unstructured":"Schoder H, Larson SM, Yeung HW. PET\/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45 Suppl 1:72S\u201381S.","journal-title":"J Nucl Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-010-0963-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-010-0963-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-010-0963-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T16:36:40Z","timestamp":1572971800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-010-0963-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,12]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1245\/s10434-010-0963-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,12]]}}}